3B Blackbio Dx Limited Q4 FY25 results deck summary

Results deck of 28 May 2025, summarised by AI from the filing.

FY25 consolidated revenue ₹9,646.86 cr; MDx revenue ₹8,428.25 cr; management guides 15%–20% growth for FY 2025–26.

Key takeaways

1. Export growth Export sales (Non-COVID) rose nearly 97% to ₹1,710.41 cr in 2024-25, driven by UK subsidiary.
2. New products dPCR assays expected to launch by Q2/Q3 FY 2025-26; NGS panels to be launched commercially.
3. Competition Increased competition in MDx industry due to growth attracting new players.

Original filing on BSE

3B Blackbio Dx Limited earnings call, investor presentation and press release summaries

• Q1 FY27: Results deck (13 Aug 2026)
• Q4 FY26: Earnings call (1 Jun 2026), Results deck (29 May 2026)
• Q3 FY26: Earnings call (21 Feb 2026), Results deck (6 Feb 2026)
• Q2 FY26: Results deck (13 Nov 2025)
• Q1 FY26: Earnings call (19 Aug 2025)
• Q4 FY25: Results deck (28 May 2025)
• Other events: Strategy deck (14 Aug 2025)